Motor Neuron Disease News and Research

RSS

DZNE and Intravacc receive € 2.5 million EU funding to develop a prototype ALS vaccine

DZNE and Intravacc B.V., a world leading contract development and manufacturing organization (CDMO) of preventive and therapeutic vaccines, have been awarded a funding of € 2.5 million from the European Union (EIC Transition Grant) to further develop a prototype ALS vaccine, including process development, scale-up, and toxicology study.

6 Jul 2022

£4.25 million research grant seeks to discover meaningful treatments for motor neuron disease

A group of charities and government research organisations has awarded £4.25 million to MND experts at six UK universities to kick start collaborative efforts to end motor neuron disease (MND).

20 Jun 2022

New DNA test can quickly and accurately identify a range of hard-to-diagnose genetic diseases

A new DNA test, developed by researchers at the Garvan Institute of Medical Research in Sydney and collaborators from Australia, UK and Israel, has been shown to identify a range of hard-to-diagnose neurological and neuromuscular genetic diseases quicker and more-accurately than existing tests.

4 Mar 2022

€10 million ‘precision medicine’ research project launched to provide new insights into ALS

An ambitious academic, clinical and industry research programme that will provide new insights into our understanding of Motor Neuron Disease (MND), also known as Amyotrophic Lateral Sclerosis (ALS), was launched today by Tánaiste and Irish Minister for Enterprise, Trade and Employment, Leo Varadkar T.D.

1 Mar 2022

First platform trial for ALS hopes to accelerate the development of effective treatments

A new paper in Annals of Neurology describes the approach, structure, and launch of the HEALEY ALS Platform Trial– the first platform trial for amyotrophic lateral sclerosis (ALS) designed to accelerate the development of effective and breakthrough treatments for people with the illness.

28 Feb 2022

Novel molecular pathway shared by two neurodegenerative disorders discovered

Scientists from two independent research teams have discovered how the mislocalization of a protein, known as TDP-43, alters the genetic instructions for UNC13A, providing a possible therapeutic target that could also have implications in treating amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other forms of dementia.

28 Feb 2022

Research reveals why a common genetic variant worsens outcomes for people with ALS and FTD

A pioneering new study led by UCL and National Institutes of Health (NIH) scientists has revealed, for the first time, why a common genetic variant worsens disease outcomes for people with the devastating adult-onset neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

24 Feb 2022

Winners of the first CERF Medical Engineering Prize for ALS Research announced

The Cullen Education and Research Fund announced the recipients of the first CERF Medical Engineering Prize for ALS Research: Dr. Leigh Hochberg, Dr. Conor Walsh, and Dr. Sabrina Paganoni.

8 Feb 2022

Blood tests may enable simpler, more accurate early diagnosis of ALS

Blood tests may enable more accurate diagnosis of ALS at an earlier stage of the disease. As described in a study by researchers at University of Gothenburg and Umeå University, it involves measuring the blood level of a substance that, as they have also shown, varies in concentration depending on which variant of ALS the patient has.

28 Jan 2022

Scientists reveal toxic astrocyte changes in ALS

Scientists at the Francis Crick Institute have revealed harmful changes in supporting cells, called astrocytes, in Amyotrophic Lateral Sclerosis (ALS) in two publications in Brain and Genome Research.

19 Jan 2022

Novel biomarker can be used to identify disease progression in ALS

An international collaboration led by Flinders University has identified a potential biomarker for amyotrophic lateral sclerosis, also known as Motor Neuron Disease, providing a way to test the effectiveness of future clinical trials.

13 Jan 2022

Scientists determine structure of the molecule associated with ALS for the first time

Scientists have determined for the first time the structure of the molecule associated with amyotrophic lateral sclerosis (ALS) and multiple other neurodegenerative diseases.

9 Dec 2021

Targeting the brain should be the focus of ALS therapy, not just spinal cord

The brain is indeed a target for treating ALS (amyotrophic lateral sclerosis), Northwestern Medicine scientists have discovered.

4 Dec 2021

ALS also causes retinal alterations, study reveals

Amyotrophic lateral sclerosis (ALS), characterized by harm to brain neurons and to the spinal cord, also affects the tissue of the retina, according to a study headed up by Universidad Complutense de Madrid.

16 Nov 2021

Identifying an important protein for motor coordination

News-Medical speaks to Professor Jorge Ruas about how he has identified an important protein involved in motor coordination.

10 Nov 2021

Blood lipid biomarkers associated with lower risk of ALS

Some blood lipid biomarkers linked to cardiovascular disease risk are also associated with a lower risk of amyotrophic lateral sclerosis (ALS) suggest the findings of a large epidemiology study published online in the Journal of Neurology Neurosurgery & Psychiatry.

14 Sep 2021

A single blood-based biomarker can help indicate underlying neurodegeneration

Levels of a protein called neurofilament light chain (NfL) in the blood can identify those who might have neurodegenerative diseases such as Down's syndrome dementia, motor neuron disease (ALS) and frontotemporal dementia, when clinical symptoms are not definitive

7 Jun 2021